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ABSTRACT
Objective Transvaginal sonography (TVS) is core to any
ovarian cancer screening strategy. General-population
screening involves older postmenopausal women in whom
ovarian visualization is difficult because of decreasing
ovarian size and lack of follicular activity. We report
on factors affecting the visualization of postmenopausal
ovaries in the multicenter United Kingdom Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS).
Methods The UKCTOCS is a randomized controlled trial
of 202 638 postmenopausal women with 50 639 women
in the ultrasound scan arm. TVS is the primary screening
modality in the ultrasound scan arm. Age, education,
ethnicity, body mass index (BMI), previous pelvic surgery,
lifestyle and reproductive factors, and a personal/family
history of cancer were assessed for their effects on ovarian
visualization at the initial TVS.
Results Between 11 June 2001 and 18 August 2007,
43 867 women underwent TVS. The median age and
BMI of the women were 60.6 (interquartile range (IQR),
9.9) years and 25.7 (IQR, 5.8), respectively. The right
ovary was visualized in 29 297 (66.8%) and the left
ovary was visualized in 28 726 (65.5%). Visualization of
ovaries decreased with previous hysterectomy (odds ratio
(OR) = 0.534; 95% CI, 0.504–0.567), previous tubal
ligation (OR = 0.895; 95% CI, 0.852–0.940), increasing
age (OR = 0.953; 95% CI, 0.950–0.956), unilateral
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oophorectomy (OR = 0.224; 95% CI, 0.186–0.269) and
being overweight (OR = 0.918; 95% CI, 0.876–0.962)
or obese (OR = 0.715; 95% CI, 0.677–0.755). Increased
visualization was observed with a history of infertility
(OR = 1.134; 95% CI, 1.005–1.279) and increasing
age (in years) at menopause (OR = 1.005; 95% CI,
1.001–1.009).
Conclusions Several factors affect the visualization of
postmenopausal ovaries. Their impact needs to be taken
into consideration when developing quality assurance
for ovarian ultrasound scanning or comparing study
results as their prevalence may differ between populations.
Copyright  2013 ISUOG. Published by John Wiley &
Sons Ltd.
INTRODUCTION
Transvaginal sonography (TVS) is core to any ovarian
cancer screening strategy. Its efficacy both as a first- and
a second-line test is being evaluated in the multicenter
United Kingdom Collaborative Trial of Ovarian Can-
cer Screening (UKCTOCS)1 and in several other ovarian
cancer screening trials worldwide2–4. Visualization of
ovaries underpins the identification of abnormal ovarian
morphology. However, ovarian visualization can be dif-
ficult in general-population screening that involves older
postmenopausal women with decreasing ovarian size and
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. ORIGINAL PAPER
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lack of follicular activity. The Kentucky Ovarian Can-
cer Screening group, in their report on efficacy of TVS
screening in asymptomatic women at a single center,
showed that it was possible to visualize the ovaries in
79.2% of the 57 214 scans performed in 14 469 women
(including premenopausal women with a family history
of ovarian cancer) enrolled on the trial between 1987
and 19992. A more recent study, of 515 asymptomatic
postmenopausal women, has also reported similar visual-
ization rates: 86.3% for the right ovary and 78% for the
left ovary5. Of these 515 women, 481 attended for a repeat
TVS 12 months later6. The right ovary was seen in 85.8%
and the left ovary in 77.7% of women. For both scans, the
right ovary was seen in 80% and the left ovary was seen in
68%. More variable visualization rates, of between 57%
and 71%, have been reported in different subgroups from
the ovarian screening arm of the Prostate Lung Colorec-
tal and Ovarian Cancer (PLCO) study7,8. Although there
is some description of the baseline characteristics of the
study populations, in none was the effect of confounding
factors, such as hysterectomy, assessed on ovarian visu-
alization. As TVS is likely to remain part of any ovarian
cancer screening strategy, this is essential if we are to com-
pare study results or develop quality assessment measures
to assess sonographers. We report on factors impacting
the visualization of ovaries in women undergoing TVS in
the ultrasound scan arm of the UKCTOCS.
METHODS
The UKCTOCS is a randomized controlled trial of ovarian
cancer screening of 202 638 postmenopausal women par-
ticipants in the general population. The participants are
allocated to a control group (no screening), a multimodal
group (annual screening with CA 125 as a primary test
and TVS as a secondary test) or an ultrasound scan group
(annual screening with TVS) in a 2:1:1 ratio. Women were
recruited through 13 trial centers located in National
Health Service (NHS) Hospitals in England, Wales
and Northern Ireland. Written consent was obtained
from all participants. Women were included in the trial
if they were postmenopausal (defined as >12 months
amenorrhea following a natural or surgical menopause or
>12 months of hormone replacement therapy commenced
for menopausal symptoms) and were ≥ 50 and 70–74
years of age. They were excluded if they had a history of
bilateral oophorectomy, active malignancy (women with
a past history of malignancy were eligible if they had
no documented persistent or recurrent disease), increased
risk of ovarian cancer because of familial predisposition
or a previous history of ovarian cancer. Following con-
firmation of eligibility, 50 639 women were randomized
to the ultrasound scan arm. At recruitment, women
completed a baseline questionnaire, which included age,
lifestyle factors, and reproductive, medical and family his-
tories (Table 1). Women were sent a postal questionnaire
3.5 years after randomization in which information on
education, smoking and alcohol use was obtained. Details
of recruitment and design are described elsewhere1,9.
A detailed ultrasound scan protocol1 addressed all
issues with regard to scanning, including technique, clas-
sification of morphological findings, further management
algorithms and collection and storage of the ultrasound
data. The majority of the scans (carried out from 2001 to
2007) were performed using the Kretz SA2000 (Kretztech-
nik AG, Zipf, Austria) ultrasound machine. For the main
trial, annual scans were performed by Type 1 sonogra-
phers who were certified sonographers, trained midwives
or doctors in the NHS trained in gynecological scanning.
If the results of the annual scan were abnormal then
women had a repeat scan, which was performed by Type
2 sonographers who were senior sonographers (mostly
superintendent level), experienced certified gynecologists
or radiologists. Where women found TVS unacceptable,
transabdominal sonography (TAS) was performed.
At the annual screen visit, the sonographer initially
ascertained whether the woman had previously undergone
a hysterectomy or a unilateral oophorectomy. The first
step on scanning was to decide if the ovaries were: (a) seen;
(b) not seen, but a good view of the iliac vessels was
obtained; and (c) not seen, with a poor view of the iliac ves-
sels secondary to bowel, fibroids or other pelvic structures.
Definitions of morphology and algorithms for the clas-
sification of scans and further management are detailed
elsewhere1. All data obtained from scans were entered on
the central Web-based trial-management system9.
In this study, women in the ultrasound scan arm of the
UKCTOCS who underwent TVS at the first annual screen
were included. Those who only had transabdominal scans
were excluded.
The UKCTOCS study was approved by the UK
North West Multicentre Research Ethics Committees
(North West MREC 00/8/34). It is registered as an
International Standard Randomized Controlled Trial (no.
ISRCTN22488978).
Statistical analysis
Frequency distributions of baseline characteristics of the
population were derived. Visualization was defined as
ovaries ‘seen’ and the rates were calculated based on
all included scans. Visualization rates of the right and
the left ovary were calculated separately. As they were
proportionally similar, all further analyses were confined
to visualization rates of the right ovary. All recorded fac-
tors (age, body mass index (BMI), hormone replacement
therapy (HRT) use, previous hysterectomy, unilateral
oophorectomy with intact uterus (LONH), presence of
fibroids, years from menopause, previous contraceptive
pill use, miscarriages, parity, infertility history, tubal liga-
tion, ever smoker, alcohol use, educational qualification,
personal history of breast cancer and ethnicity) were eval-
uated for their effect on visualization of ovaries. Logistic
regression with backward stepwise elimination (probabil-
ity of removal = 0.05) was used to determine which of the
abovementioned variables were independently significant
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2013; 42: 472–477.
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Table 1 Baseline characteristics of women attending first-year
transvaginal scan
Characteristic
Total
(n = 43 867)
Visualization
of RO
(n = 29 297)
Age (years)
50–54 years 7983 (18.2) 5932 (74.3)
55–59 years 12 335 (28.1) 8750 (70.9)
60–64 years 10 416 (23.7) 6995 (67.2)
65–69 years 8313 (19.0) 4984 (60.0)
70–74 years 4820 (11.0) 2636 (54.7)
Years from LMP
< 5 years 10 277 (23.4) 7741 (75.3)
5 to<10 years 9030 (20.6) 6411 (71.0)
10 to<15 years 8462 (19.3) 5801 (68.6)
≥ 15 years 16 098 (36.7) 9344 (58.0)
BMI group
Underweight (BMI 15 to
<20 kg/m2)
516 (1.2) 330 (64.0)
Normal (BMI 20 to<25 kg/m2) 18 054 (41.2) 12 598 (69.8)
Overweight (BMI 25 to
<30 kg/m2)
16 010 (36.5) 10 685 (66.7)
Obese (BMI ≥ 30 kg/m2) 9083 (20.7) 5560 (61.2)
Data errors/missing information 204 (0.5) 124 (60.8)
Ethnicity
White 42 328 (96.5) 28 209 (66.6)
Black 615 (1.4) 428 (69.6)
Asian 374 (0.9) 280 (74.9)
Other 339 (0.8) 247 (72.9)
Missing information 211 (0.5) 133 (63.0)
History of breast cancer
Personal 1614 (3.7) 1031 (63.9)
In sister 1910 (4.4) 1258 (65.9)
In mother 2601 (5.9) 1798 (69.1)
In sister and mother 199 (0.5) 134 (67.3)
None in first-degree relative 37 820 (86.2) 25 253 (66.8)
History of infertility
Yes, nulliparous 290 (0.7) 198 (68.3)
Yes, parous 1032 (2.4) 758 (73.4)
No 42 418 (96.7) 28 250 (66.6)
Missing information 127 (0.3) 91 (71.7)
History of miscarriage
Yes 13 546 (30.9) 9041 (66.7)
Missing information 582 (1.3) 373 (64.4)
Parity
Nulliparous 4572 (10.5) 3073 (67.2)
1 5227 (12.3) 3594 (68.8)
2 18 823 (43.5) 12 746 (67.7)
3 9922 (22.5) 6591 (66.4)
>3 5207 (11) 3214 (61.7)
Missing information 116 (0.3) 79 (68.1)
OCP use 26 888 (63) 18 469 (68.7)
HRT use 8356 (19.4) 5685 (68.0)
Previous hysterectomy 8201 (18.7) 4420 (53.9)
Previous contralateral oophorectomy (LO)
Yes 704 (1.6) 537 (76.3)
No 43 163 (98.4) 28 760 (66.6)
Excluding those with
previous hysterectomy
246 (0.6) 201 (81.7)
Previous sterilization 9552 (21.8) 6189 (64.8)
Ever smoker
Yes 15 007 (34.2) 10 203 (68.0)
Missing information 2820 (6.4) 1624 (57.6)
Alcohol use
Yes 25 884 (59) 17 667 (68.3)
Missing information 10 156 (23.2) 6485 (63.9)
Table 1 Continued
Characteristic
Total
(n = 43 867)
Visualization
of RO
(n = 29 297)
Level of education
None of the options given 3672 (8.4) 2511 (68.4)
Secondary education 1125 (2.6) 794 (70.6)
Clerical/administrative 8429 (19.2) 5663 (67.2)
Higher secondary education 3157 (7.2) 2083 (66.0)
Nursing/teaching 6885 (15.7) 4869 (70.7)
College/university degree 10 146 (23.1) 6705 (66.1)
Missing information 10 453 (23.8) 6672 (63.8)
Data are given as n (%). BMI, body mass index; HRT, hormone
replacement therapy; LMP, last menstrual period; LO, left ovary;
OCP, oral contraceptive pill; RO, right ovary.
in predicting ovarian visualization rates. All analyses were
undertaken using Stata 12 (StataCorp LP, College Station,
TX, USA).
RESULTS
Between 11 June 2001 and 18 August 2007, 48 230
women in the ultrasound scan arm had an initial scan
performed by 109 sonographers. Of these women, 43 867
had a TVS (42 401 had a TVS only and 1466 had both a
TVS and a TAS) and were included in the analysis. Women
who underwent a TAS only (n = 4363) were excluded. The
median age of the 43 867 women was 60.6 (IQR, 9.9).
The majority of women were white, one in five was obese,
18.7% had previously had a hysterectomy and 1.6% had
undergone a unilateral oophorectomy (Table 1).
The right ovary (RO) was visualized in 29 297 (66.8%)
scans and the left ovary (LO) in 28 726 (65.5%) (Table 2).
As the visualization of the RO and LO was proportionally
similar, further analyses were limited to the RO. In women
in whom the RO was visualized, the median age at the
scan was 59.9 (IQR, 9.5) years. Visualization of the RO
declined with increasing age (Figure 1a; Table 1) and
being overweight or obese (Figure 1b; Table 1).
In total, 40 801 women had complete data with regard
to factors assessed and were included in the model. In
27 717 of these women, the right ovary was visualized.
From the logistic regression model, age at scan, raised
BMI, previous hysterectomy, previous tubal ligation and
LONH were identified as significant predictors at the
5% level, with fibroids, history of infertility and age
Table 2 Overall visualization of ovaries in 43 867 women
undergoing transvaginal sonography
Visualization Right ovary Left ovary
Seen 29 297 (66.8) 28 726 (65.5)
Not seen
Good view 11 905 (27.1) 12 428 (28.3)
Poor view 1942 (4.4) 2009 (4.6)
Previous oophorectomy 723 (1.6) 704 (1.6)
Values are given as n (%).
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2013; 42: 472–477.
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Figure 1 Visualization of right ovary on transvaginal scan in
different age groups (a) and in different body mass index (BMI)
groups (b). Bars represent means, and 95% confidence limits are
shown.
at menopause only of marginal significance. Previous
hysterectomy (OR = 0.534; 95% CI, 0.504–0.567),
increasing age (OR = 0.953; 95% CI, 0.950–0.956),
previous tubal ligation (OR = 0.895; CI, 0.852–0.940),
LONH (OR = 0.224; 95% CI, 0.186–0.269) and being
overweight (OR = 0.918; 95% CI, 0.876–0.962) or
obese (OR = 0.715; 95% CI, 0.677–0.755) were asso-
ciated with decreased visualization (Table 3). Increased
visualization was associated with a history of infer-
tility (OR = 1.134; 95% CI, 1.005–1.279), increasing
age at menopause (OR = 1.005; 95% CI, 1.001–1.009)
and the presence of fibroids (OR = 1.075; 95% CI,
1.013–1.140). There was a non-significant trend toward
increased visualization in women of Black (OR = 1.226;
95% CI, 0.965–1.557) or Asian (OR = 1.178; 95% CI,
0.986–1.407) origin. History of contraceptive pill use or
miscarriage, parity, smoking and alcohol use, educational
qualification, and a personal history of breast cancer had
no additional impact on visualization of ovaries.
DISCUSSION
This is the largest study describing factors affecting
ovarian visualization on TVS in postmenopausal women.
Our results show a 47% decrease in ovarian visualization
in women who have previously undergone hysterectomy
and a 5% decrease with each increasing year of age. A
78% decrease in visualization is noted in women who
have an intact uterus but unilateral oophorectomy, an
11% decrease in those who have had tubal ligation, a 9%
decrease in overweight women and a 29% decrease in
obese women. A history of infertility has a 14% increase in
visualization of the ovary. There is also a non-significant
increase in visualization of ovaries, of 22% and 17%,
respectively, in women of Black and Asian origin.
The strengths of our study are the large sample size,
involving participants from the general population, a
multicenter design and performance of scans by over
100 sonographers, all of which increases the external
validity of the findings. The two other major factors
that can affect visualization are skill/experience of the
individual sonographer and the overall quality of the
team. While there are no studies comparing visualization
rates with experience of sonographers, Timmerman et al.
have shown that operator experience is a significant
factor in accurately identifying malignant from benign
lesions on ultrasound scans10. In an image review
study of 300 women (166 premenopausal and 134
postmenopausal), an accuracy of 92% was achieved by the
two most-experienced operators, while accuracy dropped
to 82–87% for the less-experienced operators. Similarly,
there was very good interobserver agreement between
the two most-experienced operators but this varied with
the less-experienced operators. It is also likely that
organization and leadership of the team, together with
training, support and monitoring of the sonographers,
adds to the quality of scanning at any individual center.
We are currently undertaking work which compares
scanning between sonographers and trial centers and
describes in detail the quantitative methods for quality
assessment of TVS in postmenopausal women, adjusted
for the non-subjective factors identified and quantified
here to impact on ovarian visualization.
Our findings of decreased ovarian visualization with
previous hysterectomy confirm the report from the PLCO
trial that women with previous hysterectomy were less
likely (47%) to have their ovaries seen in comparison
with women who had no previous gynecological surgery
of their ovaries (61%)8. The most likely reason for this is
the loss of anatomical landmarks with the absence of the
uterus, making it harder to identify the ovary. Changes
in the relative position of the ovaries and in the position
and size of the uterus, and the presence of fibroids, bowel
in the pelvis and adhesions secondary to surgery could
also impact on visualization. Except for the presence
of fibroids, information on the other factors was not
routinely recorded so we are unable to comment on their
effect. Unlike previous reports, the presence of fibroids
did not decrease visualization (although the evidence was
not strong, being only just significant at the 5% level)
but this could be a result of the fact that these would be
atrophic in this postmenopausal cohort and were likely to
have been of smaller size and asymptomatic in the past.
Copyright  2013 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2013; 42: 472–477.
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Table 3 Factors affecting visualization of right ovary on transvaginal scan
Factor Odds ratio Standard error P 95% CI
Previous hysterectomy (yes) 0.534 0.016 < 0.0001 0.504–0.567
Previous tubal ligation (yes) 0.895 0.022 < 0.0001 0.852–0.940
Age at scan (years) 0.953 0.001 < 0.0001 0.950–0.956
Age at last menstrual period (years) 1.005 0.001 0.006 1.001–1.009
History of infertility (yes) 1.134 0.069 0.040 1.005–1.279
Unilateral (left) oophorectomy with intact uterus (yes) 0.224 0.020 < 0.0001 0.186–0.269
Presence of fibroids (yes) 1.075 0.032 0.016 1.013–1.140
Ethnicity*
White (reference)
Black 1.226 0.149 0.095 0.965–1.557
Asian 1.178 0.106 0.071 0.986–1.407
Other 1.216 0.154 0.121 0.949–1.559
BMI group†
Normal (BMI 20 to<25 kg/m2) (reference)
Underweight (BMI 15 to <20 kg/m2) 0.834 0.091 0.099 0.673–1.034
Overweight (BMI 25<30 kg/m2) 0.918 0.021 < 0.0001 0.876–0.962
Obese (BMI ≥ 30 kg/m2) 0.715 0.019 < 0.0001 0.677–0.755
*Overall P for ethnicity = 0.0404. †Overall P for BMI group < 0.0005. BMI, body mass index.
We noted that unilateral oophorectomy in the absence of
hysterectomy was also associated with a significant (78%)
decrease in visualization of the remaining ovary. Previous
data also suggest that women who have had unilateral
oophorectomy with hysterectomy have an accelerated
decline in the function of the remaining ovary and an
earlier menopause than do women who have had a
hysterectomy alone during the premenopausal period11.
This should lead to a reduction in the size of the remaining
ovary and reduced visualization. In the PLCO study,
visualization of the ovary contralateral to the side of
oophorectomy was also decreased (42%) when compared
with women who had no previous gynecological surgery
(61%)8. No difference in visualization of ovaries was
observed between women who had previously undergone
gynecological surgery (61%) and those who underwent
sterilization (60%). However, in our study, an 11%
decrease in visualization was noted in those who had
undergone tubal ligation. It is difficult to speculate why
this may be the case as the latter is a minor procedure;
however, it is known to be associated with iatrogenic
hydrosalpinx12 and it is possible that this may have
obscured the view of the ovary.
The visualization of ovaries was reduced in women
with increasing age (a 5% decrease in the OR with each
year), whereas increasing age at menopause improved
visualization (although this was only marginally sig-
nificant). Ovaries were visualized in 71% of 55- to
59-year-old women compared with 55% of women
70–74 years of age (Table 1). This is similar to the
PLCO study, which reported decreased visualization in
older women and increased rates in those who attained
menopause in later years (after 55 years of age)8. There
was a significant decrease in visualization of ovaries with
BMI >30. Increased fat leads to poor penetration of
sound waves beyond the focal point, leading to poor
views on ultrasound scans13. In TVS this is reduced as
the transducer is closer to the pelvic structures, making
them easier to visualize. However, transducer movement
may be restricted secondary to thigh and vulval obesity,
especially in morbidly obese women.
Unlike other factors, information on smoking and alco-
hol use were obtained from the follow-up questionnaire
completed 3 to 4 years following the first scan. Although
unlikely, these habits may have changed from the time
when the first scan was performed to when the data
were actually collected. Other limitations include a small
proportion (3.3%) of women who underwent both TVS
and TAS and in whom it was not possible to deter-
mine whether the ovaries were visualized on TAS or
TVS as this was not separately documented. In addition,
the proportion of Black (1.4%), Asian (0.9%) and other
ethnic-minority (0.8%) women in the study was small.
This might have led to the lack of significant difference in
visualization rates of ovaries.
In conclusion, several factors affect visualization of
ovaries on TVS, with previous hysterectomy, previous
LONH, tubal ligation, BMI and age having the largest
impacts. Adjustments for these factors are necessary
when developing quality assurance for ovarian ultrasound
scanning or comparing results between studies as their
prevalence may differ between populations.
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